Clarus Therapeutics Holdings, Inc. (CRXT) is a publicly traded company in the Unknown sector. Across all available filings, 15 corporate insiders have executed 41 transactions totaling $20.2M, demonstrating a bearish sentiment with -$20.2M in net insider flow. The most recent transaction on Jun 7, 2022 involved a transaction of 1,922 shares valued at $0.
No significant insider buying has been recorded for CRXT in the recent period.
No significant insider selling has been recorded for CRXT in the recent period.
Based on recent SEC filings, insider sentiment for CRXT is bearish with an Insider Alignment Score of 0/100 and a net flow of -$20.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Clarus Therapeutics Holdings, Inc. (CRXT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 15 insiders are actively trading CRXT stock, having executed 41 transactions in the past 90 days. The most active insider is Associates II Lp Tmp (Executive), who has made 6 transactions totaling $9.5M.
Get notified when executives and directors at CRXT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 7, 2022 | Cermak Elizabeth | Executive | Award | 1,922 | $N/A | $0 | |
| Jun 7, 2022 | Hernandez Joseph | Executive | Award | 1,922 | $N/A | $0 | |
| Jun 7, 2022 | Kenneth Amory John | Executive | Award | 1,922 | $N/A | $0 | |
| Jun 7, 2022 | M. Murphy Kimberly | Executive | Award | 1,922 | $N/A | $0 | |
| Jun 7, 2022 | A. Prygocki Mark Sr | Executive | Award | 1,922 | $N/A | $0 | |
| Apr 25, 2022 | Hernandez Joseph | Executive | Other | 1,237,500 | $N/A | $0 | |
| Apr 25, 2022 | Hernandez Joseph | Executive | Other | 65,000 | $N/A | $0 | |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 1,663,126 | $2.53 | $4.2M | Large |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 13,630 | $2.53 | $34.5K | |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 1,164 | $2.53 | $2.9K | |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 7,585 | $2.53 | $19.2K | |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 5,722 | $2.53 | $14.5K | |
| Apr 20, 2022 | Lp Tmp Associates | Executive | Sale | 2,061,685 | $2.53 | $5.2M | Large |
| Apr 20, 2022 | II Lp Tmp Associates | Executive | Sale | 13,630 | $2.53 | $34.5K | |
| Apr 20, 2022 | II Lp Tmp Associates | Executive | Sale | 2,061,685 | $2.53 | $5.2M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 13 | $20.2M | 100.0% |
Award(A) | 22 | $0 | 0.0% |
Other(J) | 4 | $0 | 0.0% |
Exercise(M) | 2 | $0 | 0.0% |
Insider selling pressure at Clarus Therapeutics Holdings, Inc. has increased, with 15 insiders executing 41 transactions across all time. Total sales of $20.2M significantly outpace purchases of $0, resulting in a net outflow of $20.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.